Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Howard Liebman, MD

    TitleProfessor of Medicine, Don Feinstein Chair in Hematology
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 3466
    Health Sciences Campus
    Los Angeles California 90089-9172
    Phone+1 323 865 3950
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Since 1999, Dr. Liebman is the author or co-author of over 100 medical articles and chapters and has led well over a hundred lectures across the United States, South America, Europe and Japan on a variety of medical topics. He has also been the recipient of millions of dollars in research grants, reviewed a number of medical journals and is a former Chair of the Massachusetts Governor’s Task Force subcommittee on experimental therapies and clinical trials for AIDS. In addition to his academic responsibilities, Dr. Liebman is an attending staff member of the LAC+USC Medical Center, the USC/Norris Comprehensive Cancer Center and the Keck Hospital of USC.

      Dr. Liebman also is on the forefront of research in thrombotic and hemorrhagic disorders. His lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, arterial thrombosis and thrombosis associated with cancer chemotherapy. Additional studies are elucidating the role of prothrombotic defects in developing osteonecrosis. He has also been the principle investigator on a number of clinical trials in the management of immune thrombocytopenia. His research group has made important discoveries on the role of infectious agents in the development of immune thrombocytopenia. Dr. Liebman is also internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy and has served on the Cancer and Thrombosis Guideline Committee of the American Society of Clinical Oncology.


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      American College of Physicians Fellow

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Liebman H, Weitz IC. Autoimmune Hemolytic Anemia. Med Clin North Am. 2017 Mar; 101(2):351-359. PMID: 28189175.
        View in: PubMed
      2. Liebman H, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM. Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. Haematologica. 2016 Nov; 101(11):1327-1332. PMID: 27515248.
        View in: PubMed
      3. Liebman H. Immune modulation for autoimmune disorders: evolution of therapeutics. Semin Hematol. 2016 Apr; 53 Suppl 1:S23-6. PMID: 27312159.
        View in: PubMed
      4. Liebman H, O'Connell C. Incidental venous thromboembolic events in cancer patients: what we know in 2016. Thromb Res. 2016 Apr; 140 Suppl 1:S18-20. PMID: 27067973.
        View in: PubMed
      5. Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman H, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015 Oct; 55(10):2398-403. PMID: 25989361.
        View in: PubMed
      6. Piatek CI, El-Hemaidi I, Feinstein DI, Liebman H, Akhtari M. Management of immune-mediated cytopenias in pregnancy. Autoimmun Rev. 2015 Sep; 14(9):806-11. PMID: 25981747.
        View in: PubMed
      7. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman H, Tempero MA, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. PMID: 25605844.
        View in: PubMed
      8. O'Connell CL, Liebman H. Approach to the management of incidental venous thromboembolic events in patients with cancer. J Natl Compr Canc Netw. 2014 Nov; 12(11):1557-60. PMID: 25361802.
        View in: PubMed
      9. Liebman H. Thrombocytopenia in cancer patients. Thromb Res. 2014 May; 133 Suppl 2:S63-9. PMID: 24862148.
        View in: PubMed
      10. Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013 Nov; 91(5):423-36. PMID: 23927437.
        View in: PubMed
      11. Liebman H, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol. 2013 Sep; 162(5):693-701. PMID: 23829485.
        View in: PubMed
      12. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman H, Tempero MA, Wong SL, Prestrud AA, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204. PMID: 23669224.
        View in: PubMed
      13. Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, Cines DB, Cooper N, Godeau B, Greinacher A, Imbach P, Khellaf M, Klaassen RJ, Kühne T, Liebman H, Mazzucconi MG, Newland A, Pabinger I, Tosetto A, Stasi R. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013 Apr 4; 121(14):2596-606. PMID: 23361904.
        View in: PubMed
      14. Matsuo K, Yessaian AA, Lin YG, Pham HQ, Muderspach LI, Liebman H, Morrow CP, Roman LD. Predictive model of venous thromboembolism in endometrial cancer. Gynecol Oncol. 2013 Mar; 128(3):544-51. PMID: 23262205.
        View in: PubMed
      15. Zwicker JI, Liebman H, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7. PMID: 23240761.
        View in: PubMed
      16. Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, Mackman N, Green R, Liebman H. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012 Sep; 130(3):361-8. PMID: 22542362.
        View in: PubMed
      17. Piatek C, O'Connell CL, Liebman H. Treating venous thromboembolism in patients with cancer. Expert Rev Hematol. 2012 Apr; 5(2):201-9. PMID: 22475288.
        View in: PubMed
      18. O'Connell CL, Razavi PA, Liebman H. Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J Clin Oncol. 2011 Nov 1; 29(31):4208-9; author reply 4209-10. PMID: 21969510.
        View in: PubMed
      19. Liebman H, Khorana A, Kessler C. Clinical roundtable monograph. The oncologist's role in management of venous thromboembolism. Clin Adv Hematol Oncol. 2011 Jan; 9(1):suppl 1-15. PMID: 21361081.
        View in: PubMed
      20. Liebman H, Pullarkat V. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Hematology Am Soc Hematol Educ Program. 2011; 2011:384-90. PMID: 22160062.
        View in: PubMed
      21. Rabin DU, Kuter DJ, Liebman H, Bussel JB. What do healthcare providers ask their patients with immune thrombocytopenia? Am J Hematol. 2010 Aug; 85(8):629-31. PMID: 20658595.
        View in: PubMed
      22. Cines DB, Liebman H. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1155-61. PMID: 19932425.
        View in: PubMed
      23. Liebman H. Preface. Hematol Oncol Clin North Am. 2009 Dec; 23(6):xi. PMID: 19932424.
        View in: PubMed
      24. Cheung E, Liebman H. Thyroid disease in patients with immune thrombocytopenia. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1251-60. PMID: 19932432.
        View in: PubMed
      25. Zwicker JI, Liebman H, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009 Nov 15; 15(22):6830-40. PMID: 19861441.
        View in: PubMed
      26. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman H, Key NS, Mackman N. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2010 Jun; 125(6):511-2. PMID: 19854471.
        View in: PubMed
      27. Cheung E, Liebman H. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics. 2009; 3:57-62. PMID: 19707396.
        View in: PubMed
      28. Cines DB, Bussel JB, Liebman H, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009 Jun 25; 113(26):6511-21. PMID: 19395674.
        View in: PubMed
      29. Liebman H. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S33-6. PMID: 19245932.
        View in: PubMed
      30. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S2-14. PMID: 19245930.
        View in: PubMed
      31. O'Connell CL, Liebman H. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond. Expert Rev Hematol. 2008 Dec; 1(2):175-82. PMID: 21082922.
        View in: PubMed
      32. Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman H. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. PMID: 18671791.
        View in: PubMed
      33. Alexy T, Tucker S, Boyle S, Rowe VL, Weaver FA, Liebman H. Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia. J Vasc Surg. 2008 Aug; 48(2):377-81. PMID: 18515040.
        View in: PubMed
      34. Liebman H. Heparin-induced thrombocytopenia: diagnosis and management. Vascular. 2008 Mar-Apr; 16 Suppl 1:S71-6. PMID: 18544310.
        View in: PubMed
      35. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman H, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2; 371(9610):395-403. PMID: 18242413.
        View in: PubMed
      36. Liebman H. Immune thrombocytopenia (ITP): an historical perspective. Hematology Am Soc Hematol Educ Program. 2008; 205. PMID: 19074083.
        View in: PubMed
      37. Liebman H. Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2008; 212-8. PMID: 19074085.
        View in: PubMed
      38. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 1; 25(34):5490-505. PMID: 17968019.
        View in: PubMed
      39. Weitz IC, Liebman H. The role of oral anticoagulants in tumor biology. Semin Thromb Hemost. 2007 Oct; 33(7):695-8. PMID: 18000797.
        View in: PubMed
      40. Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007 Oct; 44(4 Suppl 5):S24-34. PMID: 18096469.
        View in: PubMed
      41. Liebman H, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol. 2007 Sep; 14(5):557-73. PMID: 17934365.
        View in: PubMed
      42. Tarantino MD, Bussel JB, Cines DB, McCrae KR, Gernsheimer T, Liebman H, Wong WY, Kulkarni R, Grabowski E, McMillan R. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood. 2007 Jun 15; 109(12):5527; author reply 5528. PMID: 17554071.
        View in: PubMed
      43. O'Connell CL, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman H. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006 Oct 20; 24(30):4928-32. PMID: 17050877.
        View in: PubMed
      44. Levine AM, Vigen C, Gravink J, Mack W, Watts CH, Liebman H. Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr. 2006 Aug 15; 42(5):572-7. PMID: 16837864.
        View in: PubMed
      45. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman H. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006 Feb; 33(2):355-7. PMID: 16465669.
        View in: PubMed
      46. Liebman H. Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control. 2005 Sep; 12 Suppl 1:11-6. PMID: 16179899.
        View in: PubMed
      47. Rajan SK, Espina BM, Liebman H. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005 Jun; 129(6):818-24. PMID: 15953010.
        View in: PubMed
      48. Tallman MS, Brenner B, Serna Jde L, Dombret H, Falanga A, Kwaan HC, Liebman H, Raffoux E, Rickles FR. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res. 2005 Mar; 29(3):347-51. PMID: 15661272.
        View in: PubMed
      49. Deitcher SR, Ngengwe R, Kaplan R, Liebman H, Kaplan K, Blinder M. Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases. Clin Adv Hematol Oncol. 2004 Jun; 2(6):382-4; discussion 384-6. PMID: 16163209.
        View in: PubMed
      50. Ru X, Liebman H. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003 Oct; 123(2):278-81. PMID: 14531909.
        View in: PubMed
      51. Liebman H, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003; 111(4-5):235-8. PMID: 14693169.
        View in: PubMed
      52. Sutherland DE, Weitz IC, Liebman H. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003 Jan; 72(1):43-52. PMID: 12508268.
        View in: PubMed
      53. Bowdish ME, Weaver FA, Liebman H, Rowe VL, Hood DB. Anticoagulation is an effective treatment for aortic mural thrombi. J Vasc Surg. 2002 Oct; 36(4):713-9. PMID: 12368731.
        View in: PubMed
      54. Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman H. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002 Sep; 118(4):1166-9. PMID: 12199802.
        View in: PubMed
      55. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman H. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002 Aug; 88(2):213-20. PMID: 12195692.
        View in: PubMed